CB-12181, a new azasugar-based matrix metalloproteinase/tumor necrosis factor-α converting enzyme inhibitor, inhibits vascular endothelial growth factor-induced angiogenesis in vitro and retinal neovascularization in vivo

Current Neurovascular Research

Volumn 6, Issue 3, 2009, Pages 140-147

  Chikaraishi, Yuichi ^a   Shimazawa, Masamitsu ^a   Yokota, Koichi ^b   Yoshino, Koichiro ^b   Hara, Hideaki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

^b 1 5 5 Minatojima Minamimachi   (Japan)

Author keywords

Human umbilical vein endothelial cells (HUVECs); Matrix metalloproteinase (MMP); Mice; Neovascularization; Oxygen induced retinopathy; Retina; TNF converting enzyme (TACE)

Indexed keywords

3,4,5, TRIHYDROXY 1 [4' PHENOXYBENZENESULFONYL] PIPERIDINE 2 HYDROXY AMIDE; ANGIOGENESIS INHIBITOR; CB 12181; HETEROCYCLIC COMPOUND; OXYGEN; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMBIENT AIR; ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COCULTURE; CONTROLLED STUDY; DRUG EFFICACY; ENDOTHELIUM CELL; FEMALE; FIBROBLAST; FLUORESCENCE ANGIOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INCUBATION TIME; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; RETINA NEOVASCULARIZATION; UMBILICAL VEIN;

EID: 68549126960     PISSN: 15672026     EISSN: None     Source Type: Journal    
DOI: 10.2174/156720209788970072     Document Type: Article

References (42)

1. Barnett, JM, McCollum, GW, Fowler, JA, Duan, JJ, Kay, JD, Liu, RQ, Bingaman, DP, Penn, JS. (2007) Pharmacologic and genetic manipulation of MMP-2 and -9 affects retinal neovascularization in rodent models of OIR. Invest Ophthalmol Vis Sci 48: 907-915.
2. Berglin, L, Sarman, S, van der Ploeg, I, Steen, B, Ming, Y, Itohara, S, Seregard, S, Kvanta, A. (2003) Reduced choroidal neovascular membrane formation in matrix metalloproteinase-2-deficient mice. Invest Ophthalmol Vis Sci 44: 403-408. (Pubitemid 36134302)
3. Bishop, ET, Bell, GT, Bloor, S, Broom, IJ, Hendry, NF, Wheatley, DN. (1999) An in vitro model of angiogenesis: basic features. Angiogenesis 3: 335-344. (Pubitemid 129643976)
4. Black, RA, Rauch, CT, Kozlosky, CJ, Peschon, JJ, Slack, JL, Wolfson, MF, Castner, BJ, Stocking, KL, Reddy, P, Srinivasan, S, Nelson, N, Boiani, N, Schooley, KA, Gerhart, M, Davis, R, Fitzner, JN, Johnson, RS, Paxton, RJ, March, CJ, Cerretti, DP. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factoralpha from cells. Nature 385: 729-733. (Pubitemid 27098094)
5. Bradley, J, Ju, M, Robinson, GS. (2007) Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141-148. (Pubitemid 46440632)
6. Bussolino, F, Mantovani, A, Persico, G. (1997) Molecular mechanisms of blood vessel formation. Trends Biochem Sci 22: 251-256. (Pubitemid 27310945)
7. Carmeliet, P, Jain, RK. (2000) Angiogenesis in cancer and other diseases. Nature 407: 249-257.
8. Carmeliet, P. (2005) Angiogenesis in life, disease and medicine. Nature 438: 932-936.
9. Cezar-de-Mello, PF, Vieira, AM, Nascimento-Silva, V, Villela, CG, Barja- Fidalgo, C, Fierro, IM. (2008) ATL-1, an analogue of aspirintriggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol 153: 956-965. (Pubitemid 351328942)
10. Chikaraishi, Y, Shimazawa, M, Hara, H. (2007) New quantitative analysis, using high-resolution images, of oxygen-induced retinal neovascularization in mice. Exp Eye Res 84: 529-536. (Pubitemid 46204694)
11. Chikaraishi Y, Matsunaga N, Shimazawa M, Hara H. (2008) Rifampicin inhibits the retinal neovascularization in vitro and in vivo. Exp Eye Res 86: 131-137. (Pubitemid 350212885)
12. Das, A, McGuire, PG, Eriqat, C, Ober, RR, DeJuan, E Jr, Williams, GA, McLamore, A, Biswas, J, Johnson, DW. (1999a) Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 40: 809-813. (Pubitemid 29109465)
13. Das, A, McLamore, A, Song, W, McGuire, PG. (1999b) Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 117: 498-503. (Pubitemid 29169645)
14. Demircan, N, Safran, BG, Soylu, M, Ozcan, AA, Sizmaz, S. (2006) Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye 20: 1366-1369. (Pubitemid 44921137)
15. Donovan, D, Brown, NJ, Bishop, ET, Lewis, CE. (2001) Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Angiogenesis 4: 113-121.
16. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31.
17. Folkman, J. (2006) Angiogenesis. Annu Rev Med 57: 1-18.
18. Friis, T, Kjaer Sorensen, B, Engel, AM, Rygaard, J, Houen, G. (2003) A quantitative ELISA-based co-culture angiogenesis and cell proliferation assay. APMIS 111: 658-668. (Pubitemid 37130037)
19. Garcia, C, Bartsch, DU, Rivero, ME, Hagedorn, M, McDermott, CD, Bergeron-Lynn, G, Cheng, L, Appelt, K, Freeman, WR. (2002) Efficacy of Prinomastat (AG3340), a matrix metalloprotease inhibitor, in treatment of retinal neovascularization. Curr Eye Res 24: 33-38. (Pubitemid 34765359)
20. Hanahan, D. (1997) Signaling vascular morphogenesis and maintenance. Science 277: 48-50.
21. Ingber, D. (1991) Extracellular matrix and cell shape: potential control points for inhibition of angiogenesis. J Cell Biochem 47: 236-241.
22. Izuta, H, Chikaraishi, Y, Shimazawa, M, Mishima, S, Hara, H. (2007) 10- Hydroxy-2-decenoic acid, a major fatty acid from Royal Jelly, inhibits VEGF-induced angiogenesis in human umbilical vein endothelial cells. Evid Based Complement Alternat Med Oct 22, doi:10.1093/ecam/nem152.
23. Jager, RD, Mieler, WF, Miller, JW. (2008) Age-related macular degeneration. N Engl J Med 358: 2606-2617.
24. Jin, M, Kashiwagi, K, Iizuka, Y, Tanaka, Y, Imai, M, Tsukahara, S. (2001) Matrix metalloproteinases in human diabetic and nondiabetic vitreous. Retina 21: 28-33. (Pubitemid 32151759)
25. Kauffmann, DJ, van Meurs, JC, Mertens, DA, Peperkamp, E, Master, C, Gerritsen, ME. (1994) Cytokines in vitreous humor: interleukin-6 is elevated in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 35: 900-906. (Pubitemid 24079820)
26. Lainer-Carr, D, Brahn, E. (2007) Angiogenesis inhibition as a therapeutic approach for inflammatory synovitis. Nat Clin Pract Rheumatol 3: 434-442. (Pubitemid 47193549)
27. Lainer, DT, Brahn, E. (2005) New antiangiogenic strategies for the treatment of proliferative synovitis. Expert Opin Investig Drugs 14: 1-17.
28. Lambert, V, Munaut, C, Jost, M, Noël, A, Werb, Z, Foidart, JM, Rakic, JM. (2002) Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am J Pathol 161: 1247-1253.
29. Limb, GA, Chignell, AH, Green, W, LeRoy, F, Dumonde, DC. (1996) Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 80: 168-173. (Pubitemid 26058553)
30. Limb, GA, Hollifield, RD, Webster, L, Charteris, DG, Chignell, AH. (2001) Soluble TNF receptors in vitreoretinal proliferative disease. Invest Ophthalmol Vis Sci 42: 1586-1591. (Pubitemid 32520752)
31. Majka, S, McGuire, P, Colombo, S, Das, A. (2001) The balance between proteinases and inhibitors in a murine model of proliferative retinopathy. Invest Ophthalmol Vis Sci 42: 210-215. (Pubitemid 32059432)
32. Majka, S, McGuire, PG, Das, A. (2002) Regulation of matrix metalloproteinase expression by tumor necrosis factor in a murine model of retinal neovascularization. Invest Ophthalmol Vis Sci 43: 260-266. (Pubitemid 34032468)
33. Matsunaga, N, Chikaraishi, Y, Shimazawa, M, Yokota, S, Hara, H. (2007) Vaccinium myrtillus (Bilberry) extracts reduce angiogenesis in vitro and in vivo. Evid Based Complement Alternat Med Oct 27, doi:10.1093/ecam/nem151.
34. Moriyama, H, Tsukida, T, Inoue, Y, Yokota, K, Yoshino, K, Kondo, H, Miura, N, Nishimura S. (2004) Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents. J Med Chem 47: 1930-1938. (Pubitemid 38453912)
35. Noda, K, Ishida, S, Inoue, M, Obata, K, Oguchi, Y, Okada, Y, Ikeda, E. (2003) Production and activation of matrix metalloproteinase-2 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 44: 2163-2170. (Pubitemid 36520313)
36. Parvathy, S, Karran, EH, Turner, AJ, Hooper, NM. (1998) The secretases that cleave angiotensin converting enzyme and the amyloid precursor protein are distinct from tumour necrosis factor-alpha convertase. FEBS Lett 431: 63-65. (Pubitemid 28330853)
37. Shojaei, F, Ferrara, N. (2007) Antiangiogenesis to treat cancer and intraocular neovascular disorders. Lab Invest 87: 227-230. (Pubitemid 46353946)
38. Smith, LE, Wesolowski, E, McLellan, A, Kostyk, SK, D'Amato, R, Sullivan, R, D'Amore, PA. (1994) Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 35: 101-111.
39. Steen, B, Sejersen, S, Berglin, L, Seregard, S, Kvanta, A. (1998) Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 39: 2194-2200. (Pubitemid 28455093)
40. Szekanecz, Z, Koch, AE. (2008) Vascular involvement in rheumatic diseases: 'vascular rheumatology'. Arthritis Res Ther 10: 224.
41. Tsuzuki, T, Shibata, A, Kawakami, Y, Nakagawa, K, Miyazawa, T. (2007) Conjugated eicosapentaenoic acid inhibits vascular endothelial growth factor-induced angiogenesis by suppressing the migration of human umbilical vein endothelial cells. J Nutr 137: 641-646. (Pubitemid 46397496)
42. Weskamp, G, Schlöndorff, J, Lum, L, Becherer, JD, Kim, TW, Saftig, P, Hartmann, D, Murphy, G, Blobel, CP. (2004) Evidence for a critical role of the tumor necrosis factor alpha convertase (TACE) in ectodomain shedding of the p75 neurotrophin receptor (p75NTR). J Biol Chem 279: 4241-4249. (Pubitemid 38199011)